- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Carmex expands skin care portfolio with fragrance-free cream
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
SAN ANTONIO — Mission Pharmacal has launched what it called an alternative to pill therapy for osteoporosis.
The drug maker announced Thursday the availability of Binosto (alendronate sodium) effervescent tablets for buffered oral solution in pharmacies. The drug is used to treat osteoporosis in postmenopausal women and increase bone mass in men with the condition.
"We are very pleased to add Binosto to our line of bone-health products," Mission Pharmacal president of commercial operations Terry Herring said. "With this exciting new treatment option, physicians can rest easily, knowing they are prescribing an easy-to-take and proven therapy for their osteoporosis patients that protects against fracture risk at the hip and spine."